Inhibition of Farnesoid X Receptor Signaling Shows Beneficial Effects in Human Obesity

Overview

Journal J Hepatol

Publisher Elsevier

Specialty Gastroenterology

Date 2015 Mar 10

PMID 25747705

Citations 16

Authors

Frank J Gonzalez

Changtao Jiang

William H Bisson

Andrew D Patterson

Affiliations

Soon will be listed here.

Citing Articles

Farnesoid X receptor and fibroblast growth factor 15/19 as pharmacological targets.

Maliha S, Guo G Liver Res. 2025; 5(3):142-150.

PMID: 39957843 PMC: 11791795. DOI: 10.1016/j.livres.2021.02.002.

Postbiotic Impact on Host Metabolism and Immunity Provides Therapeutic Potential in Metabolic Disease.

Fang H, Rodrigues E-Lacerda R, Barra N, Kukje Zada D, Robin N, Mehra A Endocr Rev. 2024; 46(1):60-79.

PMID: 39235984 PMC: 11720174. DOI: 10.1210/endrev/bnae025.

Multispecies probiotics complex improves bile acids and gut microbiota metabolism status in an fermentation model.

Liu W, Li Z, Ze X, Deng C, Xu S, Ye F Front Microbiol. 2024; 15:1314528.

PMID: 38444809 PMC: 10913090. DOI: 10.3389/fmicb.2024.1314528.

Ceramides are fuel gauges on the drive to cardiometabolic disease.

Wilkerson J, Tatum S, Holland W, Summers S Physiol Rev. 2024; 104(3):1061-1119.

PMID: 38300524 PMC: 11381030. DOI: 10.1152/physrev.00008.2023.

The supplementation of the multi-strain probiotics WHHPRO™ alleviates high-fat diet-induced metabolic symptoms in rats via gut-liver axis.

Chen C, Gao K, Chen Z, Zhang Q, Ke X, Mao B Front Nutr. 2024; 10:1324691.

PMID: 38274203 PMC: 10808617. DOI: 10.3389/fnut.2023.1324691.

References

Trauner M, Graziadei I . Review article: mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases. Aliment Pharmacol Ther. 1999; 13(8):979-96. DOI: 10.1046/j.1365-2036.1999.00596.x. View

Miyake J, Taylor J, Du E, Castellani L, Lusis A, Davis R . Transgenic expression of cholesterol-7-alpha-hydroxylase prevents atherosclerosis in C57BL/6J mice. Arterioscler Thromb Vasc Biol. 2002; 22(1):121-6. DOI: 10.1161/hq0102.102588. View

Turnbaugh P, Gordon J . The core gut microbiome, energy balance and obesity. J Physiol. 2009; 587(Pt 17):4153-8. PMC: 2754355. DOI: 10.1113/jphysiol.2009.174136. View

Kars M, Yang L, Gregor M, Mohammed B, Pietka T, Finck B . Tauroursodeoxycholic Acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women. Diabetes. 2010; 59(8):1899-905. PMC: 2911053. DOI: 10.2337/db10-0308. View

Li T, Owsley E, Matozel M, Hsu P, Novak C, Chiang J . Transgenic expression of cholesterol 7alpha-hydroxylase in the liver prevents high-fat diet-induced obesity and insulin resistance in mice. Hepatology. 2010; 52(2):678-90. PMC: 3700412. DOI: 10.1002/hep.23721. View

Ratziu V, de Ledinghen V, Oberti F, Mathurin P, Wartelle-Bladou C, Renou C . A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. J Hepatol. 2010; 54(5):1011-9. DOI: 10.1016/j.jhep.2010.08.030. View

Iguchi Y, Nishimaki-Mogami T, Yamaguchi M, Teraoka F, Kaneko T, Une M . Effects of chemical modification of ursodeoxycholic acid on TGR5 activation. Biol Pharm Bull. 2011; 34(1):1-7. DOI: 10.1248/bpb.34.1. View

Li T, Matozel M, Boehme S, Kong B, Nilsson L, Guo G . Overexpression of cholesterol 7α-hydroxylase promotes hepatic bile acid synthesis and secretion and maintains cholesterol homeostasis. Hepatology. 2011; 53(3):996-1006. PMC: 3079544. DOI: 10.1002/hep.24107. View

Tsuchida T, Shiraishi M, Ohta T, Sakai K, Ishii S . Ursodeoxycholic acid improves insulin sensitivity and hepatic steatosis by inducing the excretion of hepatic lipids in high-fat diet-fed KK-Ay mice. Metabolism. 2011; 61(7):944-53. DOI: 10.1016/j.metabol.2011.10.023. View

10.

Matsubara T, Li F, Gonzalez F . FXR signaling in the enterohepatic system. Mol Cell Endocrinol. 2012; 368(1-2):17-29. PMC: 3491147. DOI: 10.1016/j.mce.2012.05.004. View

11.

Sayin S, Wahlstrom A, Felin J, Jantti S, Marschall H, Bamberg K . Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab. 2013; 17(2):225-35. DOI: 10.1016/j.cmet.2013.01.003. View

12.

Gonzalez F . Nuclear receptor control of enterohepatic circulation. Compr Physiol. 2013; 2(4):2811-28. PMC: 6608752. DOI: 10.1002/cphy.c120007. View

13.

Li F, Jiang C, Krausz K, Li Y, Albert I, Hao H . Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity. Nat Commun. 2013; 4:2384. PMC: 6595219. DOI: 10.1038/ncomms3384. View

14.

Duboc H, Tache Y, Hofmann A . The bile acid TGR5 membrane receptor: from basic research to clinical application. Dig Liver Dis. 2014; 46(4):302-12. PMC: 5953190. DOI: 10.1016/j.dld.2013.10.021. View

15.

Joyce S, Gahan C . The gut microbiota and the metabolic health of the host. Curr Opin Gastroenterol. 2014; 30(2):120-7. DOI: 10.1097/MOG.0000000000000039. View

16.

Ryan K, Tremaroli V, Clemmensen C, Kovatcheva-Datchary P, Myronovych A, Karns R . FXR is a molecular target for the effects of vertical sleeve gastrectomy. Nature. 2014; 509(7499):183-8. PMC: 4016120. DOI: 10.1038/nature13135. View

17.

Qi Y, Jiang C, Cheng J, Krausz K, Li T, Ferrell J . Bile acid signaling in lipid metabolism: metabolomic and lipidomic analysis of lipid and bile acid markers linked to anti-obesity and anti-diabetes in mice. Biochim Biophys Acta. 2014; 1851(1):19-29. PMC: 4219936. DOI: 10.1016/j.bbalip.2014.04.008. View

18.

Sepe V, Renga B, Festa C, DAmore C, Masullo D, Cipriani S . Modification on ursodeoxycholic acid (UDCA) scaffold. discovery of bile acid derivatives as selective agonists of cell-surface G-protein coupled bile acid receptor 1 (GP-BAR1). J Med Chem. 2014; 57(18):7687-701. DOI: 10.1021/jm500889f. View

19.

Festa C, Renga B, DAmore C, Sepe V, Finamore C, De Marino S . Exploitation of cholane scaffold for the discovery of potent and selective farnesoid X receptor (FXR) and G-protein coupled bile acid receptor 1 (GP-BAR1) ligands. J Med Chem. 2014; 57(20):8477-95. DOI: 10.1021/jm501273r. View

20.

Neuschwander-Tetri B, Loomba R, Sanyal A, Lavine J, Van Natta M, Abdelmalek M . Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2014; 385(9972):956-65. PMC: 4447192. DOI: 10.1016/S0140-6736(14)61933-4. View